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Loss of heterozygosity (LOH) on the short arm of chromosome 8, at 8p12–p23, is one of the most frequent genetic events in both
breast and ovarian cancer, suggesting the location of a shared tumour suppressor gene. Microcell-mediated chromosome transfer of
chromosome 8 suppresses tumorigenicity and growth of colorectal and prostate cancer cell lines, further supporting the presence of
a tumour suppressor gene on 8p. We have taken a candidate gene approach to try to identify this tumour suppressor gene at 8p12–
p23. BNIP3L, which has sequence homology to pro-apoptotic proteins and the ability to suppress colony formation in soft agar, is
located at 8p21, within a region of ovarian cancer LOH, breast cancer LOH and prostate cancer metastasis suppression. BNIP3L
expression was assessed by both RT–PCR and Northern blot analysis in breast and ovarian cancer cell lines and found to be
expressed at similar levels relative to expression in their respective normal epithelial cell lines. Genetic analysis of BNIP3L in 40
primary ovarian and 25 primary breast tumours identified one somatic, intronic mutation in one ovarian tumour, as well as several
polymorphisms, including one resulting in an amino-acid substitution. These data suggest that BNIP3L is unlikely to be the target of 8p
LOH in ovarian or breast cancer.
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Breast and ovarian cancers are the leading and fifth leading causes
of cancer deaths, respectively, in women in developed countries.
Both cancers are epithelial in origin and share some common
genetic and epidemiological risk factors (Claus et al, 1996). While
some of the genes involved in predisposition to familial breast and
ovarian cancer are known (Claus et al, 1996; Welsch and King,
2001), little is understood about the somatic molecular changes
that occur during the development of sporadic breast and ovarian
cancer. Few genes have been found to be frequently down-
regulated in these tumours, and even fewer to carry frequent
mutations (Liu and Ganesan, 2002).
The highest rates of loss of heterozygosity (LOH) in breast
cancer are found at 17p, 8p and 7q, while in ovarian cancer they
are at 17p, 17q, 8p, 22q and 18q (Callahan et al, 1992; Shelling et al,
1995; Phelan et al, 1998; Seitz et al, 2000; Pribill et al, 2001). LOH
has been reported at 8p12–8p23 in over 50% of primary breast
tumours (Wang et al, 1999; Yokota et al, 1999). Similarly, LOH
occurs in over 50% of ovarian tumors at p12–p23 (Brown et al,
1999; Wright et al, 1998). The occurrence of this common region of
LOH in breast and ovarian cancer suggests that 8p12–23 probably
harbours one or more tumour suppressor genes that are somati-
cally inactivated in these neoplasms.
The BNIP3L gene is located between markers D8S1752 and
D8S1989 that map to 8p21 in the smallest region of overlap (SRO)
identified by LOH analysis of breast and ovarian tumours (Seitz
et al, 2000; Brown et al, 1999), and to a region of prostate cancer
metastasis suppression (Nihei et al., 1996). BNIP3L encodes a
protein that is homologous to the proapoptotic protein BNIP3
(Matsushima et al, 1998; Chen et al, 1999; Imazu et al, 1999;
Yasuda et al, 1999). Several well-characterised tumour suppressor
genes such as PTEN, p53 and RB have been shown to function
through the control of apoptosis (Bellamy, 1997; Zornig et al,
2001), making BNIP3L a good candidate for an 8p tumour
suppressor gene. Like its homologue, BNIP3L contains a sequence
motif for a transmembrane domain and a putative proapoptotic
BH3 (Bcl-2 homology-3) domain (Yasuda et al, 1999). BNIP3L
interacts with the antiapoptotic viral proteins E1B19kD and BCL2
to induce cell death by altering mitochondrial membrane
permeability (Chen et al, 1999; Imazu et al, 1999; Yasuda et al,
1999). Further evidence for a possible tumour suppressor role of
the BNIP3L gene is provided by experiments showing that the
clonicity in soft agar of cervical cancer cell lines was suppressed
after transfection of the BNIP3L gene (Matsushima et al, 1998).
Considering its function and location, BNIP3L is a strong
candidate for the breast and/or ovarian cancer tumour suppressor
gene located at 8p21.
In order to determine whether BNIP3L functions as a tumour
suppressor gene in breast and/or ovarian cancer, we have analysed
its expression in ovarian and breast cancer cell lines and screened
all exons for mutations in a panel of primary ovarian and breast
cancers.
MATERIALS AND METHODS
Cell lines
Human ovarian surface epithelial cell lines (HOSE) 1.1 and
17.1, immortalised with a retroviral vector expressing human
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spapillomavirus oncogenes (Tsao et al, 1995), were cultured in
RPMI 1640 with 10% FCS. The human ovarian cancer cell lines 27
27/87, A2780, CAOV3, CI8O135, COLO316, JAM, OAW 42, PEO1,
PEO14, SKOV3 and OVCAR 3 were maintained in RPMI 1640 with
10% FCS, and HEY, DOV-13, OVCA 432, OVCAR-4, OVCAR-5 and
OVCAR-8 were maintained in MEM alpha with 10% FCS. OVCA
420 was maintained in 1:1 MCDB105:M199 with 10% FCS and
59M was maintained in DMEM with 10% FCS.
The human breast epithelial cell lines Bre-80-hTERT1 and Bre-
80-hTERT2 (gifts of R Reddel), immortalised with human
telomerase cDNA, were cultured in 1:1 RPMI 1640:MCDB 170
with 10% FCS, and MCDB 170 with 10% FCS respectively. The
human breast cancer cell lines BC 312, NB88, T-47D, ZR-75-1, BT-
20, MDA-MB-231, BT474 and BT483 were maintained in RPMI
1640 with 10% FCS with the latter two supplemented with
1mgml
 1 insulin. The cell lines 21MT-1, 21MT-2 and 21NT were
maintained in MEM alpha with 10% FCS, 10mM HEPES, 1mgml
 1
insulin, 2.8mM hydrocortisone and 0.1mM nonessential amino
acids. SK-BR-3 was maintained in DMEM with 10% FCS and MCF7
was maintained in MEM alpha with 10% FCS and 1mgml
 1 insulin.
Primary tumours
Primary ovarian tumour cells were obtained from 40 patients with
malignant ovarian neoplasms undergoing surgery (Table 2). There
were 31 serous tumours, seven endometrioid tumours and two
clear cell tumours. All patients were staged at laparotomy, in
accordance with the recommendations of the International
Federation of Gynaecology and Obstetrics (FIGO). Primary breast
tumours were obtained from 25 patients with malignant tumours
undergoing surgery (Table 3). All patients were staged at surgery,
in accordance with the recommendations of the American Joint
Committee on Cancer (AJCC) and Union Internationale Contre le
Cancer (UICC). The corresponding constitutional DNA was
available in all cases from peripheral blood. Informed consent
was obtained from all patients.
DNA and RNA isolation
Cell lines were harvested for DNA and RNA extraction at about
80% confluence. Total RNA was extracted from breast and ovarian
cell lines using the Tri-reagent (Sigma Castle Hill, New South
Wales, Australia) following the manufacturer’s instructions.
PolyA+ RNA was prepared from total RNA using Dynabeads
mRNA purification kit (Dynal, Carlton South, Victoria, Australia).
For the primary ovarian tumours, tumour tissue was dissected free
from necrotic and connective tissue and mechanically dispersed
prior to collagenase treatment (0.1mgml
 1 in Hanks balanced salt
solution). Dead and red cells were then removed by Ficoll–Paque,
and genomic DNA was extracted by the salting-out method (Miller
et al, 1988). The purity of the resulting DNA is supported by the
high frequency of LOH on chromosome 17 detected in ovarian
tumour DNA prepared by this method (Leary et al, 1995). DNA
was also extracted from peripheral blood and cell lines using the
salting-out method. For breast tumours, DNA was extracted from
snap-frozen pieces (containing at least 70% tumour cells) by
proteinase K digestion, followed by phenol/chloroform extraction.
Semiquantitative RT–PCR and Northern blot analysis
cDNA synthesis was primed with random hexamers and carried
out on 1mg of total RNA using Superscript II (Promega). Primers
pairs were designed to span at least one intron to avoid
contamination from genomic DNA. RT–PCR was performed
using 1ml cDNA incorporating
33P-dATP in a total volume of 20ml.
Reactions were multiplexed with primers for b-actin, which served
as an internal control. All primer sequences are listed in Table 1.
Products were taken out at the end of cycles 20, 25 and 30 in order
to assess amplification in the exponential phase, and these
products were then run on a 5% denaturing acrylamide gel prior
to autoradiography.
RNA was denatured and electrophoresed on a formaldehyde-
agarose gel and transferred to a nylon membrane (Amersham
Hybond N+) by capillary blotting overnight, then fixed to the
membrane by ultraviolet irradiation according to standard
protocols (Sambrook and Russell, 2001). Probe DNA was
Table 1 Primers used in the analysis of the BNIP3L gene
Sequence (50 –3 0) Size (bp)
RT-PCR
BNIP3L F ctgagtgccggagacggtcc 364
R ctgccatcttcttgtggcgaagg
b-actin F cgtgacaataaggagaagctgtgc 375
R ctcaggaggagcaatgatcttgat
Northern analysis
BNIP3L F ctgagtgccggagacggtcc 993
R ctggcatttgcggaaaagaagccc
GAPDH F atggatccagtccatgccatcactgcc 470
R atggtaccgaggtccaccaccctgttg
Homozygous deletion analysis
Exon 1 F ctgactcgagcgtctccacgtccg 444
R cccatgcctgagccaatgagctgc
Exon 2 F gacagatttcagttctgctgtgg 295
R gtgaatgagccctgtaacccacctg
Exon 3 F gcagaacattttgggagtaagaatgc 462
R ccttagttgtaaaggagtgcg
Exons 4 and 5 F gagacacaaccttatgagtttgg 640
R caccacttcacaggtcacacgc
Exon 6 F gcggtacccacaaacctttagagcc 221
R caccacttcacaggtcacacgc
DHPLC analysis
Exon 1 F ctgactcgagcgtctccacgtccg 444
R cccatgcctgagccaatgagctgc
Exon 2 F gacagatttcagttctgctgtgg 295
R gtgaatgagccctgtaacccacctg
Exon 3 F gcagaacattttgggagtaagaatgc 462
R ccttagttgtaaaggagtgcg
Exon 4 F gagacacaaccttatgagtttgg 259
R gcgtgcgcagatcaactgtgtcc
Exon 5 F cttgtcagtggacacagttgatctgc 414
R gtagaacaattgtgcaccc
Exon 6 F gcggtacccacaaacctttagagcc 221
R caccacttcacaggtcacacgc
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Figure 1 (A) Analysis of BNIP3L expression by RT–PCR in breast
cancer cell lines. RT–PCR was carried out in a multiplex reaction with b-
actin as an internal control for 20 cycles on cDNA from Bre-80-hTERT-1,
Bre-80-hTERT-2 and 13 breast cancer cell lines. (B) Quantification of
BNIP3L expression relative to b-actin.
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British Journal of Cancer (2003) 88(2), 270–276 & 2003 Cancer Research UKsynthesised by RT–PCR (see Table 1 for primer details), and
labelled with a
32P-dCTP by random priming (Amersham, Mega-
prime kit, Castle Hill, New South Wales, Australia) before being
hybridised to the membrane for 2h in ExpressHyb solution
(Clontech Inc., Palo Alto, CA, USA) at 651C. The membranes were
washed twice in 2 SSC/0.1% SDS at room temperature, then twice
in 0.1 SSC/0.1% SDS at 651C before autoradiography. Mem-
branes were then stripped with 0.5% SDS and reprobed with
GAPDH that served as an internal control.
Autoradiographs of RT–PCR and Northern blots were scanned
at 300dpi and the band intensity was determined by the
ImageQuant program (Molecular Dynamics, Sunnyvale, CA, USA).
Band intensity for BNIP3L was expressed as a proportion of the
b-actin or GAPDH value for RT–PCR and Northern analysis,
respectively, with the value for the reference epithelial cells (HOSE
17.1 or Bre-80-hTERT1) set to 1.0.
Homozygous deletion analysis
Primers were designed to amplify the six exons of the BNIP3L gene
(Table 1) and PCR performed on 20 ovarian and 15 breast cell
lines. PCR products were visualised on an agarose gel. Samples
were scored as deleted if a PCR failed when repeated with an
internal control.
LOH analysis
Analysis was carried out with the D8S137 and D8S1048 micro-
satellite markers that are located 1.4 and 0.55Mb centromeric to
the BNIP3L gene, respectively (http://www.celera.com). A measure
of 5ng of DNA was amplified by PCR for 35 cycles incorporating
33P-dATP. PCR products were run on a 5% denaturing acrylamide
gel and then visualised by autoradiography. LOH was scored by
two independent examiners as a reduction in the intensity of
one allele by at least 50%. Any discrepancies between the two
examiners were scored ‘can’t read’ (CR).
Denaturing high-performance liquid chromatography
(DHPLC) analysis
Primers were designed to amplify the coding regions of all exons
of the BNIP3L gene (Table 1). PCR products were amplified from
10 to 100ng of genomic DNA using AmpliTaq Gold (PE Applied
Biosystems) in a final volume of 20ml. Amplicons were then
denatured at 95
oC for 5min and cooled to 601C over 30min
(11Cmin
 1) prior to DHPLC. PCR products were loaded onto the
autosampler and 5ml was injected onto the Varian Helix System
(Varian, Walnut Creek, CA, USA). Samples were eluted within a
linear acetonitrile gradient consisting of buffer A (0.1 M triethyl-
ammonium acetate and 0.1mM EDTA) and buffer B (0.1 M triethyl-
ammonium acetate, 0.1mM EDTA and 25% acetonitrile) with a flow
rate of 0.45mlmin
 1. The buffer B gradient was 45% (0–0.5min),
50% (0.5–6min), 68% (6–7min), and 45% (7–8min).
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Figure 2 (A) Northern blot analysis of BNIP3L expression in breast
cancer cell lines. Each lane represents 15mg of total RNA from Bre-80-
hTERT-1, Bre-80-hTERT-2 and 8 breast cancer cell lines. (B) Quantification
of BNIP3L expression relative to GAPDH.
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Figure 3 (A) Analysis of BNIP3L expression by RT–PCR in ovarian
cancer cell lines. RT–PCR was carried out in a multiplex reaction with b-
actin as an internal control for 20 cycles on cDNA from HOSE 17.1 and
HOSE 1.1, and 16 ovarian cancer cell lines. (B) Quantification of BNIP3L
expression relative to b-actin.
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Figure 4 (A) Northern blot analysis of BNIP3L expression in ovarian
cancer cell lines. Each lane represents 15mg of total RNA from HOSE 17.1
and 16 ovarian cancer cell lines. (B) Quantification of BNIP3L expression
relative to GAPDH.
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British Journal of Cancer (2003) 88(2), 270–276 & 2003 Cancer Research UKDHPLC was carried out at both the recommended melt tempe-
rature as determined by the Stanford melt algorithm (http://
insertion.stanford.edu/melt.html) and 2 above the recommended
temperature. The recommended melt temperatures are 651C for
exon 1, 591C for exon 2, 53 and 581C for exon 3, 55 and 601C for
exon 4, 54 and 591C for exon 5 and 601C for exon 6. Analysis was
performed using the Star Workstation version 5 (Varian, Walnut
Creek, CA, USA). Samples that produced an aberrant shift in
retention time and peak shape were repeated with their
corresponding constitutional DNA to determine whether the shifts
were tumour specific.
Sequencing and cloning
All PCR products producing shifts on DHPLC were reamplified
and sequenced with both forward and reverse primers using ABI
Prism Big Dye Terminator cycle Sequencing Ready reaction kit (PE
Applied Biosystem) and analysed on an ABI 377 sequencer. In
some cases, PCR products were also cloned into the pGEM-T
vector (Promega) prior to sequencing with the M13 forward ( 21)
and reverse primers.
RESULTS
Characterisation of BNIP3L expression
BNIP3L expression was analysed by both RT–PCR and Northern
blot analysis in breast and ovarian cancer cell lines, as well as in
cell lines derived from the corresponding normal epithelial cells.
RT–PCR was performed on the immortalised human breast
epithelial cell lines Bre-80-hTERT1 and Bre-80-hTERT2 and 13
breast cancer cell lines (Figure 1A). Expression was detected in
both Bre-80-hTERT1 and Bre-80-hTERT2 and in all breast cancer
cell lines at similar levels. Quantification of BNIP3L expression
showed little variation in the 13 breast cancer cell lines when
compared with two immortalised normal breast epithelial cell lines
(Figure 1B).
Table 2 LOH status, mutation results and clinicopathological features of primary ovarian tumours
Clinicopathology LOH Mutations or SNPs
Case Histo Stage Grade D8S137 D8S1048 Spanning exon nt
a Codon Base change a.a change
35/87 SER 3C 3 LOH LOH 5 25044 137 CTT-TTT
b Leu-Phe
69/89 SER 3 2 NI LOH
35/90 SER 3B 2/3 NL NL 4 24147 IVS3-56 Del G
b and T-C
a Intronic
5/91 SER 2A 2/3 NI NL 24752 IVS3-61 Intronic
23/91 ENDO 3 2 LOH LOH 5 25199 IVS5+15 A-G Intronic
33/91 ENDO 4 3 LOH LOH
44/91 SER 3C 3 NI LOH 5 25199 IVS5+15 A-G Intronic
45/91 SER 3C NS LOH LOH
52/91 SER 2B 2 NI NL 5 25199 IVS5+15 A-G Intronic
59/91 SER 3 3 NL NI 5 25199 IVS5+15 A-G Intronic
68/91 SER 3 3 NL NL
2/92 SER 3 2 NL NI 5 25199 IVS5+15 A-G Intronic
3/92 SER 3 3 LOH LOH 5 25199 IVS5+15 A-G Intronic
4/92 SER 3B 3 NI NL
23/92 SER 3 3 CR CR
26/92 CCC 4 2 LOH LOH 2 8194 61 TCA-TCT
b Ser-Ser
5 25199 IVS5+15 A-G Intronic
39/92 SER 3 2 NI NI
52/92 SER 3 2 NI NL 5 25199 IVS5+15 A-G Intronic
62/92 SER 3C 2/3 LOH LOH
66/92 ENDO 3C 3 NI NL
67/92 ENDO 1C 2/3 NL NL
76/92 SER 3 2/3 LOH NI 5 25199 IVS5+15 A-G Intronic
3/93 SER 3C 3 NL CR 2 8243 IVS2+11 C-T Intronic
4/93 SER 3 1/2 NL CR 5 25199 IVS5+15 A-G Intronic
5/93 SER 3C 2/3 NI NI
6/93 SER 3C 2/3 LOH NI
8/93 SER 3C 2/3 LOH LOH
10/93 SER 3C 2/3 NL NL 5 25199 IVS5+15 A-G Intronic
12/93 CCC 3 2/3 NI NL 2 8209 66 TCC-TCA
b Ser-Ser
13/93 SER 3C NS NI NI
35/93 SER 3C 3 NI LOH
61/93 ENDO 4 2 NI LOH 2 8209 66 TCC-TCG
b Ser-Ser
5 25199 IVS5+15 A-G Intronic
65/93 ENDO 3 2/3 NI NI 5 25199 IVS5+15 A-G Intronic
99/93 ENDO 4 3 NL NL 5 25199 IVS5+15 A-G Intronic
108/93 SER 3C 2 NL NI 5 25199 IVS5+15 A-G Intronic
14/94 SER 1A NS NL NL
23/94 SER 3 3 NI NL 5 25199 IVS5+15 A-G Intronic
25/94 SER 3C 2 NL NL
34/94 SER 3C 3 NI ND 5 25199 IVS5+15 A-G Intronic
70/94 SER 3C 2 NL ND
aBases counted from ATG start codon; NS=not specified; NL=no loss; LOH=loss of heterozygosity; NI=not informative; CR=can’t read; ND=not done.
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British Journal of Cancer (2003) 88(2), 270–276 & 2003 Cancer Research UKBNIP3L expression was also examined by Northern blotting
in a subset of eight of the breast cancer cell lines. Two trans-
cripts of 1.3 and 4.4kb were detected in the Bre-80-hTERT1 and
Bre-80-hTERT2 cells and all breast cancer cell lines (Figure 2A).
Apart from T47D, in which expression was increased, there was
little variation in the level of expression in the remaining breast
cancer cell lines compared to the Bre-80-hTERT cells, although
there was some variability in the relative intensity of each
transcript (Figure 2B).
For the ovarian cancer analysis, RT–PCR was conducted on
HOSE 1.1 and HOSE 17.1, and 17 ovarian cancer cell lines
(Figure 3A). Expression was detected in both HOSE cell lines and
the 17 ovarian cancer cell lines. Of the 17 ovarian cancer cell lines,
expression was notably different only in DOV-13, which showed
about three-fold greater expression than the HOSE cell lines
(Figure 3B).
BNIP3L expression was also examined by Northern blot analysis
in a subset of 16 ovarian cancer cell lines. As in the breast cell lines,
two transcripts of 1.3 and 4.4kb were detected in the HOSE 17.1
cell line and the 16 ovarian cancer cell lines (Figure 4A). BNIP3L
was expressed by all the ovarian cancer cell lines, but the level of
expression was reduced to approximately half that of HOSE 17.1 in
six of the 16 cancer cell lines (Figure 4B). No aberrant transcripts
were detected by Northern blot analysis.
Analysis of genetic alterations at the BNIP3L locus
No homozygous deletions within BNIP3L were found in any cancer
cell line (data not shown). LOH analysis was carried out on 40
primary ovarian tumours and 25 primary breast tumours, and
their corresponding constitutional DNA to assess allelic loss at the
BNIP3L locus. Two microsatellite markers were used, D8S137 and
D8S1048. LOH was observed for at least one of the markers in 14
out of 34 (41%) ovarian tumours. A frequency of 43% (10 out of
23) and 46% (12 out of 26) LOH was observed in informative
ovarian tumours for D8S137 and D8S1048, respectively (Table 2).
No correlation was found between LOH at either marker and
tumour grade or histology. However, there was a statistically
significant trend for LOH with later stage tumours (P¼0.03).
A frequency of 33% (four out of 12) and 15% LOH (two out
of 13) was observed in informative breast tumours for D8S137
and D8S1048, respectively, with LOH observed for at least one
marker in 28% (five out of 18) of the cases (Table 3). No
correlation was found between LOH at either marker and tumour
grade or stage.
Mutation analysis
Mutation analysis of BNIP3L was carried out on the same series
of 40 primary ovarian tumours and 25 primary breast tumours
by DHPLC. In the ovarian tumours, a total of five rare and
one common polymorphisms were identified, as well as a single,
intronic somatic mutation in case three out of 93. Direct
sequencing of the PCR product from the three out of 93 tumour
failed to show any change in nucleotide sequence, so the
PCR product from both the tumour and constitutional DNA
was cloned. A c.IVS2+11C4T conversion was detected in one
out of four tumour clones and zero out of four constitutional
DNA clones, suggesting that this mutation was somatic, which
was consistent with the DHPLC chromatograph (Figure 5A). Four
of the polymorphisms were detected in coding regions in cases
35/87 (c.407C4T, Figure 5B), 26/92 (c.181A4T, Figure 5C), 12/93
(c.196C4A) and 61/93 (c.196C4G). These polymorphisms were
all silent changes except for c.407C4T, which resulted in a change
from leucine to phenylalanine. An intronic polymorphism invol-
ving a deletion and a substitution five bases apart was detected in
case 35/90 (c.IVS3-56delG; c.IVS3-61T4C). A second, common,
intronic polymorphism (IVS5+15T4C) was detected in 16/38
(42%) cases. In the breast tumours, only the common IVS5+15T4C
polymorphism was detected in 13 out of 25 (52%) of the cases.
Table 3 LOH status, mutation results and clinicopathological features of primary breast tumours
Clinicopathology LOH Mutations or SNPs
Case Histo Stage Grade D8S137 D8S1048 Spanning exon nt
a Codon Base change a.a change
1 Ductal IIIA 1 LOH NI 5 25199 IVS5+15 A-G Intronic
2 Lobular IIIA 2 NL CR
3 NS IIB 3 CR LOH
4 Med/duct IIB 3 NI CR 5 25199 IVS5+15 A-G Intronic
5 Ductal IIIB 2 NI NI
6 Ductal IIIB 2 NI NI
7 Ductal NS 2 NI NL 5 25199 IVS5+15 A-G Intronic
8 Ductal IIB NS LOH NI
9 Ductal IIA 2 LOH NI
10 Ductal IIB 3 NL NL 5 25199 IVS5+15 A-G Intronic
11 NS IIB 1 NL NL 5 25199 IVS5+15 A-G Intronic
12 Lob/duct NS 2 NI NI
13 Ductal IIIA 3 LOH NL 5 25199 IVS5+15 A-G Intronic
14 Ductal IIA 2 NL NL
15 Ductal IIB 3 NL NL 5 25199 IVS5+15 A-G Intronic
16 Ductal IIA 2 NI NI 5 25199 IVS5+15 A-G Intronic
17 Ductal IIA 3 NL NL 5 25199 IVS5+15 A-G Intronic
18 Ductal NS NS NI NL
19 Ductal NS NS NI LOH 5 25199 IVS5+15 A-G Intronic
20 Ductal NS NS CR NL
21 Ductal IIA 2 CR CR 5 25199 IVS5+15 A-G Intronic
22 Ductal NS 3 NI NL
23 Ductal IIA 3 NI NI 5 25199 IVS5+15 A-G Intronic
24 Ductal IIIB 2 NL CR 5 25199 IVS5+15 A-G Intronic
25 Ductal IIA 2 NL NL
aBases counted from ATG start codon; NS=not specified; NL=no loss; LOH=loss of heterozygosity; NI=not informative; CR=can’t read; ND=not done.
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BNIP3L encodes a proapoptotic protein and is located at 8p21
(Matsushima et al, 1998; Chen et al, 1999; Imazu et al, 1999;
Yasuda et al, 1999). BNIP3L reportedly induces cell death by
altering mitochondrial membrane permeability and has been found
to suppress clonicity in soft agar in cervical cancer cell
lines (Matsushima et al, 1998). For these reasons, it is a good
candidate for the 8p21 breast and ovarian cancer tumour
suppressor gene.
RT–PCR and Northern blot analysis showed no evidence of
frequent downregulation of BNIP3L expression in either breast or
ovarian cancer cell lines. Northern blot analysis identified two
transcripts of 1.3 and 4.4kb, which were similar in size to those
reported by Yasuda et al (1999), who identified two transcripts of
1.6 and 3.9kb. Other investigators have only observed one
transcript of either 1.45 (Matsushima et al, 1998) or 4.5kb (Chen
et al, 1998). Yasuda et al (1999) suggested that the two transcripts
may be the result of alternative splicing or that one transcript may
be derived from a closely related gene. We hypothesise that the
larger transcript is an alternatively spliced form of the BNIP3L
gene and hence quantitated BNIP3L expression as the sum of both
transcripts.
Analysis of microsatellite markers near the BNIP3L locus
detected frequencies of LOH of 43% (D8S137) and 46%
(D8S1048) in the ovarian cancers. This is consistent with reported
LOH frequencies of 45–58% at 8p21 in ovarian cancers (Lassus
et al, 2001; Pribill et al, 2001). The frequency of LOH in the breast
cancers of 27% (D8S137) and 28% overall is also consistent with a
previous report of 30% LOH at D8S137 (Seitz et al, 2000), but
lower than the 49% reported at nearby marker D8S1116 (Yokota
et al, 1999). In some cases (35 out of 87 and 26 out of 92), the LOH
scored at the microsatellite markers was confirmed by the DHPLC
analysis and sequencing.
The frequency of LOH was significantly higher in late-stage
ovarian tumours suggesting that LOH at the D8S137 and D8S1048
loci occur in the progression rather than the initiation of ovarian
cancer. A higher incidence of LOH in larger breast tumours (50%
LOH in tumours 45cm in diameter vs 11% in tumours o5cmin
diameter) observed in a previous report (Seitz et al, 2000) was not
observed in our study.
Mutation analysis was carried out by DHPLC, resulting in the
identification of one somatic mutation and six polymorphisms
in the ovarian tumours and one polymorphism in the breast
tumours. The single somatic mutation, in exon two, is a silent
mutation in the flanking intron and therefore is unlikely to affect
the protein function. The majority of the polymorphisms (four
out of six) occurred in the coding sequence, and of these,
three were silent changes in the third base of a codon. The
fourth was a nonconservative substitution of phenylalanine for
leucine at codon 137. This variant was present in the constitutional
DNA, but underwent LOH in the tumour. The remaining two
polymorphisms occurred in introns and were not located in any
donor or acceptor consensus sequences, and so are unlikely to
affect splicing.
There are five polymorphisms currently listed for BNIP3L in the
Genbank database (XM_048074), one of which occurs in the 50
UTR, one in the coding sequence (codon 48, c288G4T), and three
in the 30 UTR. There are also two listed in the SNP consortium
(http://snp.cshl.org/), one in the 50 UTR and one in the first intron.
Of these, only the polymorphism in the codon 48 could have been
identified by our analysis and it was not detected in any of the
cases analysed here.
The absence of mutations in BNIP3L in breast and ovarian
tumours, and the lack of significant downregulation of the gene in
either tumour type, suggests that BNIP3L is not the target of 8p
LOH in ovarian and breast tumours, despite its location in the
SROs of LOH in ovarian cancer (Brown et al, 1999) and breast
cancer (Yokota et al, 1999; Seitz et al, 2000). A number of other
candidate tumour suppressor genes are also located within this
region (STC1, ADAMDEC1, EXTL3, DOK2, DPYSL2, CLU and
NKX3A), but further refinement of the region by LOH analysis of
primary tumours or monochromosome-mediated chromosome
transfer (MMCT) may be necessary before identification of the
tumour suppressor is possible.
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